98%
921
2 minutes
20
Background: Malignant tumors routinely present with irregular shapes and complex configurations. The lack of customization to individual tumor shapes and standardization of procedures limits the success and application of thermal ablation.
Methods: We introduced an automated treatment model consisting of (i) trajectory and ablation profile planning, (ii) ablation probe insertion, (iii) dynamic energy delivery (including robotically driven control of the energy source power and location over time, according to a treatment plan bespoke to the tumor shape), and (iv) quantitative ablation margin verification. We used a microwave ablation system and a liver phantom (acrylamide polymer with a thermochromic ink) to mimic coagulation and measure the ablation volume. We estimated the ablation width as a function of power and velocity following a probabilistic model. Four representative shapes of liver tumors < 5 cm were selected from two publicly available databases. The ablated specimens were cut along the ablation probe axis and photographed. The shape of the ablated volume was extracted using a color-based segmentation method.
Results: The uncertainty (standard deviation) of the ablation width increased with increasing power by ± 0.03 mm (95% credible interval [0.02, 0.043]) per watt increase in power and by ± 0.85 mm (95% credible interval [0, 2.5]) per mm/s increase in velocity. Continuous ablation along a straight-line trajectory resulted in elongated rotationally symmetric ablation shapes. Simultaneous regulation of the power and/or translation velocity allowed to modulate the ablation width at specific locations.
Conclusions: This study offers the proof-of-principle of the dynamic energy delivery system using ablation shapes from clinical cases of malignant liver tumors.
Relevance Statement: The proposed automated treatment model could favor the customization and standardization of thermal ablation for complex tumor shapes.
Key Points: • Current thermal ablation systems are limited to ellipsoidal or spherical shapes. • Dynamic energy delivery produces elongated rotationally symmetric ablation shapes with varying widths. • For complex tumor shapes, multiple customized ablation shapes could be combined.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628015 | PMC |
http://dx.doi.org/10.1186/s41747-023-00381-6 | DOI Listing |
Genome Res
September 2025
Population Health Program, QIMR Berghofer, Herston, Queensland 4006, Australia;
and germline variant classification is vital for clinical management of families with hereditary breast and ovarian cancer. However, clinical classification of rare variants outside of the splice donor/acceptor ±1,2-dinucleotides remains challenging, particularly for variants that induce new or cryptic splice site usage. Here, we present SeqSplice a high-throughput RNA splicing methodology utilizing barcoded minigene constructs together with a bespoke bioinformatics pipeline for identifying and quantifying the impacts for splice-altering variants.
View Article and Find Full Text PDFEur J Cancer
September 2025
Centre for Human Genetics, University of Oxford, Oxford, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK. Electronic address:
Aim: PET-CT and MRI are used to assess disease response after head and neck cancer treatment. Equivocal findings can delay the potential for salvage curative treatment or result in over- treatment with further surgery. The aims of this study were to establish if liquid biopsy (LB) of circulating tumour DNA, could be used to aid decision-making after treatment.
View Article and Find Full Text PDFMol Ther
July 2025
Oxford Biomedica (UK) Ltd., Oxford OX4 6LT, UK; Nucleome Therapeutics Ltd., Oxford OX2 0HY, UK. Electronic address:
Chimeric antigen receptor (CAR) T cell therapy has proved remarkably successful for the treatment of hematological malignancies. However, the bespoke manufacturing of autologous CAR T cells is complex and expensive. The development of methods for in vivo engineering of T cells will enable generation of CAR T cells directly within the patient, bypassing the need for ex vivo manufacturing and thereby enabling greater access for patients.
View Article and Find Full Text PDFBMJ Health Care Inform
July 2025
Department of Medicine, Stanford University, Stanford, California, USA.
Objectives: Clinical trial enrolment is critical for the development and approval of novel cancer therapeutics, but patient identification and recruitment to clinical trials remains low and multiple trials accrue slowly or fail to meet accrual goals. Informatics solutions may facilitate clinical trial screening, ideally improving patient engagement and enrolment. Our objective is to develop and implement a system to efficiently screen queried patients for available clinical trials.
View Article and Find Full Text PDFIntroduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and mortality rates have continued to rise despite advancements in treatment. Six-monthly ultrasound surveillance is recommended by professional bodies for early detection of HCC in high-risk cohorts. However, surveillance rates remain poor; only 20% of patients attend for regular surveillance.
View Article and Find Full Text PDF